Toronto Dominion Bank
BMRN icon

Toronto Dominion Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Toronto Dominion Bank’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.7K Sell
1,004
-253,041
-100% -$14.8M ﹤0.01% 1758
2025
Q4 		$15.1M Buy
254,045
+222,836
+714% +$12.1M 0.02% 528
2025
Q3 		$1.69M Sell
31,209
-3,612
-10% -$207K ﹤0.01% 1084
2025
Q2 		$1.91M Buy
34,821
+6,189
+22% +$364K ﹤0.01% 988
2025
Q1 		$2.02M Buy
28,632
+3,770
+15% +$254K ﹤0.01% 938
2024
Q4 		$1.63M Buy
24,862
+920
+4% +$61.6K ﹤0.01% 972
2024
Q3 		$1.68M Buy
23,942
+5,711
+31% +$477K ﹤0.01% 787
2024
Q2 		$1.5M Sell
18,231
-1,523
-8% -$127K ﹤0.01% 832
2024
Q1 		$1.73M Sell
19,754
-416,497
-95% -$37.3M ﹤0.01% 798
2023
Q4 		$42.1M Sell
436,251
-471,503
-52% -$41.7M 0.06% 226
2023
Q3 		$80.3M Buy
907,754
+860,782
+1,833% +$76.6M 0.13% 119
2023
Q2 		$4.07M Sell
46,972
-7,314
-13% -$688K 0.01% 755
2023
Q1 		$5.28M Sell
54,286
-2,705
-5% -$280K 0.01% 665
2022
Q4 		$5.89M Buy
56,991
+15,868
+39% +$1.49M 0.01% 649
2022
Q3 		$3.48M Buy
41,123
+57
+0.1% +$5.08K 0.01% 745
2022
Q2 		$3.4M Buy
41,066
+1,749
+4% +$139K 0.01% 642
2022
Q1 		$3.03M Buy
39,317
+3,159
+9% +$264K ﹤0.01% 694
2021
Q4 		$3.19M Buy
36,158
+10,344
+40% +$854K ﹤0.01% 719
2021
Q3 		$2M Buy
25,814
+1,274
+5% +$101K ﹤0.01% 755
2021
Q2 		$2.05M Buy
24,540
+4
+0% +$317 ﹤0.01% 746
2021
Q1 		$1.85M Sell
24,536
-9,612
-28% -$785K ﹤0.01% 758
2020
Q4 		$2.99M Buy
34,148
+3,450
+11% +$274K 0.01% 698
2020
Q3 		$2.33M Buy
30,698
+2,906
+10% +$294K 0.01% 705
2020
Q2 		$3.43M Buy
27,792
+1,996
+8% +$198K 0.01% 665
2020
Q1 		$2.18M Sell
25,796
-6,031
-19% -$520K 0.01% 631
2019
Q4 		$2.69M Buy
31,827
+2,668
+9% +$202K ﹤0.01% 697
2019
Q3 		$1.97M Sell
29,159
-27,381
-48% -$2.11M ﹤0.01% 820
2019
Q2 		$2.42M Buy
56,540
+24,061
+74% +$2.06M 0.01% 790
2019
Q1 		$2.88M Buy
32,479
+8,147
+33% +$755K ﹤0.01% 779
2018
Q4 		$2.07M Buy
24,332
+4,743
+24% +$451K ﹤0.01% 774
2018
Q3 		$1.9M Buy
19,589
+2,040
+12% +$204K ﹤0.01% 790
2018
Q2 		$1.65M Buy
17,549
+5,527
+46% +$484K ﹤0.01% 838
2018
Q1 		$974K Buy
12,022
+1,693
+16% +$145K ﹤0.01% 823
2017
Q4 		$921K Buy
10,329
+2,960
+40% +$257K ﹤0.01% 772
2017
Q3 		$686K Buy
7,369
+5,245
+247% +$463K ﹤0.01% 726
2017
Q2 		$193K Buy
2,124
+243
+13% +$22.1K ﹤0.01% 854
2017
Q1 		$165K Buy
1,881
+401
+27% +$35.7K ﹤0.01% 866
2016
Q4 		$123K Buy
1,480
+79
+6% +$6.79K ﹤0.01% 874
2016
Q3 		$130K Buy
1,401
+513
+58% +$48.3K ﹤0.01% 881
2016
Q2 		$69K Buy
888
+3
+0.3% +$255 ﹤0.01% 789
2016
Q1 		$73K Buy
+885
New +$72K ﹤0.01% 809

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Toronto Dominion Bank's BMRN Position: Q1 2026 in Review

Toronto Dominion Bank reduced its BioMarin Pharmaceuticals (BMRN) stake by 100% in Q1 2026, selling an estimated $14.8M and leaving 1,004 shares worth $56.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1758.

Toronto Dominion Bank first reported a position in BMRN in Q1 2016 and has held it in 41 quarters since. The position peaked at $80.3M in Q3 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Toronto Dominion Bank held 1,004 shares of BioMarin Pharmaceuticals worth $56.7K as of Q1 2026.
  • Toronto Dominion Bank sold 253,041 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $14.8M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Toronto Dominion Bank's portfolio in Q1 2026, its #1758 holding.
  • Toronto Dominion Bank first reported a position in BioMarin Pharmaceuticals in Q1 2016 and has held it in 41 quarters since.
  • Toronto Dominion Bank's BioMarin Pharmaceuticals position peaked at $80.3M in Q3 2023.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Toronto Dominion Bank's 13F filing for Q1 2026, filed 15 May 2026.